10-month failure-free survival was 50 % ( lower bound of 95 % CI 39 ) in the intermittent group versus 52 % ( lower bound of 95 % CI 41 ) in the continuous group ; median failure-free survival was 12.2 months ( 95 % CI 8.8-15 .6 ) and 14.3 months ( 10.7-20 .4 ) , respectively .